BioCentury | Sep 23, 2020
Management Tracks

Gilead BD head Bender takes top job at pediatric cancer start-up Day One

...clinical oncology leadership positions at Genentech, AstraZeneca plc (LSE:AZN; NYSE:AZN), BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) and Rakuten Medical Inc....
BioCentury | Nov 14, 2019
Company News

Management tracks: Longtime Abbott CEO resigning; plus Otsuka, Bavarian Nordic, Progenics and Rakuten

...investor Velan Capital (see “Lantheus Enters Therapeutics with Progenics Takeout” ). Cancer precision therapeutics company Rakuten Medical Inc....
...group EVP at Rakuten Inc. Jonathan Block, Associate Editor Abbott Laboratories Bavarian Nordic A/S Otsuka Holdings Co. Ltd. Progenics Pharmaceuticals Inc. Rakuten Medical Inc....
BioCentury | Aug 2, 2019
Financial News

Aug. 2 Financial Quick Takes: Rakuten Medical bags another $100M; plus CGeneTech, Zecen, Qyuns and more

...Rakuten Medical raises another $100 million Rakuten Medical Inc. (San Diego, Calif.) raised $100 million in a series...
...Hiroshi Mikitani leading the round. Mikitani is also CEO of Rakuten Medical, formerly known as Aspyrian Therapeutics...
BioCentury | Jan 4, 2019
Financial News

Rakuten Aspyrian grows series C to $284M

...Erbitux to treat SCCHN and colorectal cancer. Rakuten Aspyrian Inc., San Diego, Calif. Alicia Parker ASP-1929 (RM-1929) Rakuten Inc. Rakuten Medical Inc. Epidermal...
BioCentury | Dec 22, 2018
Financial News

Rakuten Aspyrian grows series C to $284M

...Lilly and Co. (NYSE:LLY) markets cetuximab as Erbitux to treat SCCHN and colorectal cancer. Alicia Parker ASP-1929 (RM-1929) Rakuten Medical Inc....
BioCentury | Aug 31, 2018
Financial News

Rakuten’s Mikitani leads Aspyrian's $150M series C

...cetuximab as Erbitux to treat SCCHN and colorectal cancer. Rakuten Aspyrian Inc., San Diego, Calif. Mark Zipkin RM-1929 Rakuten Medical Inc....
BioCentury | Aug 23, 2018
Financial News

Rakuten’s Mikitani leads Aspyrian's $150M series C

...Eli Lilly and Co. (NYSE:LLY) markets cetuximab as Erbitux to treat SCCHN and colorectal cancer. Mark Zipkin RM-1929 Rakuten Medical Inc. Epidermal...
BioCentury | Oct 13, 2016
Translation in Brief

Zapping Tregs

...cetuximab-IR700 conjugate that triggers light-induced killing of cells expressing epidermal growth factor receptor (EGFR) . Aspyrian Therapeutics...
BioCentury | Sep 1, 2016
Distillery Therapeutics

Therapeutics: Interleukin-2 receptor α chain (CD25)

...in Phase I testing for acute myelogenous leukemia (AML), Hodgkin's disease and Non-Hodgkin's lymphoma (NHL). Aspyrian Therapeutics...
BioCentury | Mar 14, 2016
Financial News

Aspyrian Therapeutics completes venture financing

Aspyrian Therapeutics Inc. , San Diego, Calif. Business: Cancer, Antibodies Date completed: 2016-03-10 Type: Venture financing Raised: $40 million Investor: Private investor WIR Staff cancer...
Items per page:
1 - 10 of 14
BioCentury | Sep 23, 2020
Management Tracks

Gilead BD head Bender takes top job at pediatric cancer start-up Day One

...clinical oncology leadership positions at Genentech, AstraZeneca plc (LSE:AZN; NYSE:AZN), BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) and Rakuten Medical Inc....
BioCentury | Nov 14, 2019
Company News

Management tracks: Longtime Abbott CEO resigning; plus Otsuka, Bavarian Nordic, Progenics and Rakuten

...investor Velan Capital (see “Lantheus Enters Therapeutics with Progenics Takeout” ). Cancer precision therapeutics company Rakuten Medical Inc....
...group EVP at Rakuten Inc. Jonathan Block, Associate Editor Abbott Laboratories Bavarian Nordic A/S Otsuka Holdings Co. Ltd. Progenics Pharmaceuticals Inc. Rakuten Medical Inc....
BioCentury | Aug 2, 2019
Financial News

Aug. 2 Financial Quick Takes: Rakuten Medical bags another $100M; plus CGeneTech, Zecen, Qyuns and more

...Rakuten Medical raises another $100 million Rakuten Medical Inc. (San Diego, Calif.) raised $100 million in a series...
...Hiroshi Mikitani leading the round. Mikitani is also CEO of Rakuten Medical, formerly known as Aspyrian Therapeutics...
BioCentury | Jan 4, 2019
Financial News

Rakuten Aspyrian grows series C to $284M

...Erbitux to treat SCCHN and colorectal cancer. Rakuten Aspyrian Inc., San Diego, Calif. Alicia Parker ASP-1929 (RM-1929) Rakuten Inc. Rakuten Medical Inc. Epidermal...
BioCentury | Dec 22, 2018
Financial News

Rakuten Aspyrian grows series C to $284M

...Lilly and Co. (NYSE:LLY) markets cetuximab as Erbitux to treat SCCHN and colorectal cancer. Alicia Parker ASP-1929 (RM-1929) Rakuten Medical Inc....
BioCentury | Aug 31, 2018
Financial News

Rakuten’s Mikitani leads Aspyrian's $150M series C

...cetuximab as Erbitux to treat SCCHN and colorectal cancer. Rakuten Aspyrian Inc., San Diego, Calif. Mark Zipkin RM-1929 Rakuten Medical Inc....
BioCentury | Aug 23, 2018
Financial News

Rakuten’s Mikitani leads Aspyrian's $150M series C

...Eli Lilly and Co. (NYSE:LLY) markets cetuximab as Erbitux to treat SCCHN and colorectal cancer. Mark Zipkin RM-1929 Rakuten Medical Inc. Epidermal...
BioCentury | Oct 13, 2016
Translation in Brief

Zapping Tregs

...cetuximab-IR700 conjugate that triggers light-induced killing of cells expressing epidermal growth factor receptor (EGFR) . Aspyrian Therapeutics...
BioCentury | Sep 1, 2016
Distillery Therapeutics

Therapeutics: Interleukin-2 receptor α chain (CD25)

...in Phase I testing for acute myelogenous leukemia (AML), Hodgkin's disease and Non-Hodgkin's lymphoma (NHL). Aspyrian Therapeutics...
BioCentury | Mar 14, 2016
Financial News

Aspyrian Therapeutics completes venture financing

Aspyrian Therapeutics Inc. , San Diego, Calif. Business: Cancer, Antibodies Date completed: 2016-03-10 Type: Venture financing Raised: $40 million Investor: Private investor WIR Staff cancer...
Items per page:
1 - 10 of 14